Shares of Torrent Pharmaceuticals Limited surged over 4% on Monday, November 10, following the company’s robust September quarter results for FY26. The stock gained 4.02% to trade at Rs 3,724 on NSE.
The company reported a 30.4% year-on-year rise in net profit to Rs 591 crore in Q2 FY26, compared to Rs 453 crore in the same period last year. Revenue from operations increased 14.3% to Rs 3,302 crore from Rs 2,889 crore a year earlier. EBITDA grew 15.3% to Rs 1,083 crore, maintaining a stable operating margin of 32.8%, slightly higher than 32.5% in Q2 FY25.
Torrent’s India business, which remains its largest segment, grew 12% year-on-year to Rs 1,820 crore, supported by continued outperformance in focus therapies and strong momentum in the chronic portfolio, which grew 13% versus the IPM growth of 11%.
On a Moving Annual Total (MAT) basis, Torrent outperformed the market across major therapies, driven by new product launches. The company now has 21 brands among the top 500 in the Indian Pharmaceutical Market (IPM), with 15 brands generating annual sales exceeding Rs 100 crore.
Its US business also posted solid growth, with revenue rising 26% year-on-year to Rs 337 crore (around $39 million in constant currency terms), driven by new product launches achieving targeted market shares. For the first half of FY26, the company’s US revenue stood at Rs 646 crore, up 23% from the previous year.
Disclaimer:
The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
